Aclaris Therapeutics Inc (ACRS)

NASDAQ
Currency in USD
2.170
-0.030(-1.36%)
Closed
After Hours
2.180+0.010(+0.461%)

ACRS Income Statement

Advanced Income Statement
Period Ending:
2014
31/12
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa4.236.486.7629.7531.25
Total Revenues Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-31.28%+53.35%+4.3%+340.05%+5.03%
Cost Of Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa68.2234.4748.5389.77116.47
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa-63.99-27.99-41.77-60.02-85.22
Gross Profit Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-11.56%+56.26%-49.22%-43.71%-41.98%
Gross Profit Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-1,513.91%-431.8%-617.73%-201.74%-272.7%
Other Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa27.8320.5323.6225.1332.41
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa+8.02%-26.22%+15.05%+6.41%+28.96%
aa.aaaa.aaaa.aaaa.aaaa.aa-----
aa.aaaa.aaaa.aaaa.aaaa.aa27.8320.5323.6225.1332.41
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-91.82-48.52-65.38-85.15-117.63
Operating Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-10.47%+47.16%-34.76%-30.24%-38.14%
EBIT Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-2,172.23%-748.52%-967.08%-286.21%-376.42%
Net Interest Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa----8.51
Net Interest Expenses Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Interest Expense, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Interest And Investment Income
aa.aaaa.aaaa.aaaa.aaaa.aa----8.51
Other Non Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-2.48-0.42-1.142.95-
EBT, Excl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-94.3-48.94-66.53-82.21-109.12
Gain (Loss) On Sale Of Assets
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Other Unusual Items, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-0.73-2.39-24.34-4.720.27
EBT, Incl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-113.54-51.34-90.87-86.91-88.85
EBT, Incl. Unusual Items Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-38.29%+54.79%-77%+4.35%-2.23%
EBT, Incl. Unusual Items Margin
aa.aaaa.aaaa.aaaa.aaaa.aa-2,686.11%-791.98%-1,343.96%-292.11%-284.32%
Income Tax Expense
aa.aaaa.aaaa.aaaa.aaaa.aa--0.18---0.37
Net Income to Company
aa.aaaa.aaaa.aaaa.aaaa.aa-161.35-51.02-90.87-86.91-88.48
Minority Interest
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-161.35-51.02-90.87-86.91-88.48
Net Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-21.56%+68.38%-78.11%+4.35%-1.81%
Net Income Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-3,817.22%-787.03%-1,343.96%-292.11%-283.15%
Preferred Dividend and Other Adjustments
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income to Common Excl. Extra Items
aa.aaaa.aaaa.aaaa.aaaa.aa-113.54-51.15-90.87-86.91-88.48
Basic EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-2.75-1.2-1.6-1.33-1.27
Basic EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-10.13%+56.23%-33.2%+16.8%+4.89%
Diluted EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-2.75-1.2-1.6-1.33-1.27
Diluted EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-10.13%+56.23%-33.2%+16.8%+4.7%
Basic Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa41.3242.5456.7365.2169.81
Diluted Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa41.3242.5456.7365.2169.81
Dividend Per Share
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Dividend Per Share Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa-90.84-48.2-65.06--117.57
EBITDA Growth
aa.aa